12 To 15 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.5)
-
Patent number: 8859492Abstract: It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.Type: GrantFiled: May 12, 2012Date of Patent: October 14, 2014Assignee: MetalloPharm, LLCInventors: James A. Cowan, Ada S. Cowan, Donna T. Palmer
-
Publication number: 20140302123Abstract: The application provides products, which may trigger pro-apoptotic or pro-death effects on neoplastic cells and/or tissues of the human nervous system, more particularly on neoplastic cells and/or tissues of the human CNS. The products of the application can be used as anti-proliferative or tumoricid agents in the treatment and/or palliation and/or prevention of neoplasms of the human nervous system, more particularly of glioblastoma or brain stem glioma. Therefore, the application also relates to compositions, such as pharmaceutical compositions or drugs, which comprise at least one of said products, as well as to the biotechnological and medical applications of said products and compositions.Type: ApplicationFiled: October 11, 2012Publication date: October 9, 2014Inventors: Nicolas Wolfe, Monique Lafon, Nicolas Babault
-
Patent number: 8853357Abstract: The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.Type: GrantFiled: June 14, 2013Date of Patent: October 7, 2014Assignee: Cubist Pharmaceuticals, Inc.Inventors: Thomas J. Kelleher, Jan-Ji Lai, Joseph P. DeCourcey, Paul D. Lynch, Maurizio Zenoni, Auro R. Tagliani
-
Patent number: 8853359Abstract: The present invention provides peptides capable of sustaining antagonist activity against substance P for long periods of time. A peptide selected from (a) to (d) can sustain antagonist activity against substance P, analgesic activity, and anti-inflammation activity for a long period of time: (SEQ ID NO: 3) (a)?Ala-Tyr-Gln-Leu-Glu-His-Thr-DTrp-Gln-Gly-Leu- Leu-NH2; (b) a peptide consisting of a partial sequence of (a), which consists of 6 to 11 consecutive amino acids comprising at least the C-terminal Thr-DTrp-Gln-Gly-Leu-Leu-NH2 (SEQ ID NO: 18); (c) Ala-Tyr-Gln-Leu-Glu-His-Thr-Phe-Gln-DTrp-Leu-Leu-NH2 (SEQ ID NO: 4); and (d) a peptide consisting of a partial sequence of (c), which consists of 6 to 11 consecutive amino acids comprising at least the C-terminal Thr-Phe-Gln-DTrp-Leu-Leu-NH2 (SEQ ID NO: 8).Type: GrantFiled: May 31, 2010Date of Patent: October 7, 2014Assignee: University of MiyazakiInventors: Toshikazu Nishimori, Rumi Naono
-
Patent number: 8853165Abstract: The present invention relates to a peptide having bone tissue regeneration capacity and binding to a surface of apatite. More particularly, a peptide is provided having bone tissue regeneration capacity and specifically binding to a surface of apatite mineral, capable of being stably immobilized to the surface of apatite mineral to retain effective activity and exhibit bone regeneration effects for a long time, by linking an amino acid sequence having bone tissue regeneration capacity and an amino acid sequence having apatite-binding capacity to each other to thereby provide a peptide having both bone-forming effects and binding capacity to the surface of apatite mineral. A composition for bone tissue regeneration containing the peptide is further provided.Type: GrantFiled: March 9, 2011Date of Patent: October 7, 2014Assignee: Nano Intelligent Biomedical Engineering Corporation Co., Ltd.Inventors: Chong-Pyoung Chung, Yoon-Jeong Park, Sang Hoon Rhee, Jue-Yeon Lee
-
Publication number: 20140294901Abstract: The invention relates to disulfide-rich dimer molecules which inhibit binding of ?4?7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, and show high selectivity against ?4?1 binding.Type: ApplicationFiled: March 28, 2014Publication date: October 2, 2014Applicant: Protagonist Therapeutics, Inc.Inventors: Ashok Bhandari, Dinesh V. Patel, Larry C. Mattheakis
-
Publication number: 20140287001Abstract: This invention provides novel peptides and methods to prevent, control, and treat an inflammation, cancer and other disorders, particularly of the gastrointestinal tract and the lung by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound selected from i) 5-aminosalicyclic acid (5-ASA) or a derivative or a pharmaceutically acceptable salt thereof; ii) mercaptopurine; or iii) an anti-TNF therapy.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Inventor: Kunwar Shailubhai
-
Publication number: 20140287986Abstract: Novel template-fixed ?-hairpin peptidomimetics of the general formula (I): cyclo[P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-P13-P14-T1-T2] wherein the single elements T or P are ?-amino acid residues connected in either direction which, depending on their positions in the chain, are as defined in the description and the claims, and salts thereof, have the property of antagonizing the biological effect of the receptor FPR1. They can be used as medicaments to treat or prevent diseases or conditions in the areas of inflammatory diseases, allergic conditions, immunological disorders, neuroinflammation, neurological disorders, obstructive airway diseases, infectious diseases, ischemic reperfusion injuries and proliferative disorders such as e.g. cancer. These ?-hairpin peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.Type: ApplicationFiled: October 2, 2012Publication date: September 25, 2014Applicant: POLYPHOR AGInventors: Françoise Jun, Danie Obrecht, Ralf Löwe, Johann Zimmermann, Guillaume Lemercier, Eric Chevalier
-
Patent number: 8840874Abstract: The site-specific expression of selectins on endothelial cells of blood vessels during angiogenesis provides an opportunity to target anti-cancer drugs to the vascular endothelium to extend the range of the therapeutic effect. This invention describes an innovative drug targeting strategy for the selective delivery of the anticancer drugs to endothelial cells by means of polymer-drug conjugates modified with a carbohydrate ligand for the vascular selectins. A model chemotherapeutic drug, doxorubicin, and the E-selectin ligand, sLex, are attached to a biocompatible polymer (HPMA). The selective binding, cellular uptake, intracellular fate, and cell cytotoxicity of the polymer-bound drug are investigated in human endothelial cells.Type: GrantFiled: November 24, 2010Date of Patent: September 23, 2014Assignee: Ben-Gurion University of the Negev Research and Development AuthorityInventors: Ayelet David, Gonen Ashkensy, Yosi Shamay
-
Publication number: 20140271652Abstract: Disclosed are immunomodulatory polypeptides that elicit an unusual induced cytokine profile, compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry. Pharmaceutical compositions and kits, and treatment methods are also disclosed.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: Institute of Arthritis Research, LLCInventor: Craig D. Scoville
-
Patent number: 8835382Abstract: The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose.Type: GrantFiled: November 23, 2010Date of Patent: September 16, 2014Assignee: Cubist Pharmaceuticals, Inc.Inventors: Sandra O'Connor, Sophie Sun, Gaauri Naik
-
Publication number: 20140256613Abstract: Peptide compositions are disclosed that include fragments of surfactant protein-A, or a derivative thereof, wherein the fragment binds to TLR4. Methods of producing and using the peptide compositions are also disclosed.Type: ApplicationFiled: March 14, 2014Publication date: September 11, 2014Applicant: The Board of Regents of the University of OklahomaInventor: Shanjana Awasthi
-
Publication number: 20140256638Abstract: The disclosure provides for one or more peptoids, methods of manufacture thereof, and methods of use thereof, including the use of one more peptoids in neutralizing the anticoagulant activity of heparin.Type: ApplicationFiled: February 14, 2014Publication date: September 11, 2014Inventors: Dallas L. Rabenstein, Mark H. Hamza, Bruce K. Ford
-
Publication number: 20140256639Abstract: The disclosure provides for one or more peptoids, methods of manufacture thereof, and methods of use thereof, including the use of one more peptoids in neutralizing the anticoagulant activity of heparin.Type: ApplicationFiled: February 14, 2014Publication date: September 11, 2014Inventors: Dallas L. Rabenstein, Mark H. Hamza, Bruce K. Ford
-
Publication number: 20140256634Abstract: Described herein are peptides, compositions, and related methods for treating upper gastrointestinal disorders and conditions (e.g., dyspepsia, gastroparesis, post-operative gastric ileus, a functional esophageal disorder, a functional gastroduodenal disorder, gastroesophageal reflux disease (GERD), or a duodenal or stomach ulcer) as well as other conditions and disorders that are described herein.Type: ApplicationFiled: May 23, 2014Publication date: September 11, 2014Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Mark G. Currie, Daniel P. Zimmer, Angelika Fretzen, Marco Kessler, Brian Cali
-
Patent number: 8829159Abstract: Described herein are compositions and methods for cancer cell biomarkers, such as pancreatic ductal adenocarcinoma (PDAC) cell biomarkers, and binding molecules for diagnosis and treatment of cancer, e.g., PDAC. Methods of identifying “accessible” proteomes are disclosed for identifying cancer biomarkers, such as plectin-1, a PDAC biomarker. Additionally, imaging compositions are provided comprising magnetofluorescent nanoparticles conjugated to peptide ligands for identifying PDACs.Type: GrantFiled: April 14, 2009Date of Patent: September 9, 2014Assignee: The General Hospital CorporationInventors: Kimberly Kelly, Ralph Weissleder, Nabeel Bardeesy
-
Patent number: 8828940Abstract: Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.Type: GrantFiled: December 14, 2010Date of Patent: September 9, 2014Assignee: Compugen Ltd.Inventors: Yossi Cohen, Ronen Shemesh, Amir Toporik, Zurit Levine, Assaf Wool, Dvir Dahary, Iris Hecht, Galit Rotman, Michal Ayalon-Soffer
-
Patent number: 8821836Abstract: The invention provides SPARC and Albumin binding peptides for the targeting of disease sites, such as tumors, with therapeutic and diagnostic agents. In particular, compositions comprising SPARC binding peptide-Antibody Fc domain fusion proteins and methods of their use are disclosed.Type: GrantFiled: May 17, 2013Date of Patent: September 2, 2014Assignee: Abraxis BioScience, LLCInventor: Vuong Trieu
-
Patent number: 8822423Abstract: We have disclosed affinity peptides toward infliximab. More specifically we have disclosed an affinity biomatrix where the affinity peptide is covalently attached to a biocompatible, biodegradable polymer. The affinity biomatrix is useful in preparing controlled release devices for infliximab.Type: GrantFiled: May 17, 2012Date of Patent: September 2, 2014Assignee: Janssen Biotech, Inc.Inventors: Daphne Ann Salick Ryan, John Kehoe, John Wheeler, Chunlin Yang, Abla Creasey
-
Patent number: 8815807Abstract: Compositions and kits are provided having a peptide having an amino acid sequence that binds to eukaryotic cells and effects differentiation and support growth of the cells. Peptide-scaffold compositions containing at least one peptide or combinations of peptides are therapeutic agents for stimulating and promoting osteogenic activity and osteoinduction activity for cells. The scaffold is for example apatite, natural cancellous bone, demineralized natural cancellous bone, collagen, calcium phosphate, or hydroxyapatite.Type: GrantFiled: December 2, 2011Date of Patent: August 26, 2014Assignee: President and Fellows of Harvard CollegeInventors: Shigemi Nagai, Masazumi Nagai, Mindy Sungmin Gil
-
Publication number: 20140235544Abstract: The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (AMP) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous AMPs or that compete with pro-inflammatory agents or fragments of AMPs on cognate receptors without inducing disease.Type: ApplicationFiled: February 15, 2013Publication date: August 21, 2014Inventor: Yitzchak Hillman
-
Publication number: 20140235553Abstract: Disclosed are novel compositions and methods for introduction of macromolecules and nanoparticles into living cells. The invention includes a polypeptide sequence which when fused to a macromolecule or nanoparticle enhances its introduction into the cell.Type: ApplicationFiled: March 30, 2012Publication date: August 21, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corprateInventors: Jonathan Mark Petrash, Niklaus Mueller
-
Publication number: 20140235557Abstract: The invention relates to small cell penetrating peptides (CPP) derived from the scorpion toxin maurocalcine and to their use as vectors for the intracellular delivery of various drugs and agents.Type: ApplicationFiled: June 20, 2012Publication date: August 21, 2014Applicants: Commissariat A L'Energie Atomique Et Aux Energies Alternatives, Universite Joseph Fourier, Institut National De La Sante Et De La Recherche Medicale (INSERM)Inventor: Michel De Waard
-
Publication number: 20140234334Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.Type: ApplicationFiled: July 9, 2013Publication date: August 21, 2014Applicant: AMGEN INC.Inventors: Hosung MIN, Hailing HSU, Fei XIONG
-
Patent number: 8809275Abstract: Provided herein are peptoids capable of inhibiting or reversing amyloid ? (A?) fibril or plaque production. The peptoids form a helical structure with three monomers per helical turn and have at least two monomers with a side-chain having an arylalkyl group having the same chirality positioned such that the side-chains are on the same side of the peptoid. Also provided are methods of using the peptoids to inhibit or reverse aggregation of A? and methods of treating subjects with Alzheimer's disease (AD) or slowing the progression of AD.Type: GrantFiled: October 19, 2012Date of Patent: August 19, 2014Assignees: The Board of Trustees of the University of Arkansas, University of South CarolinaInventors: Shannon Servoss, Melissa Moss
-
Patent number: 8809279Abstract: Peptide compounds of the following general formula (I): R1-(AA)n-X1-X2-X3-Lys-Lys-Gln-Lys-Trp-X4-(AA)p-R2 are disclosed herein. The peptide compounds can be used as Telomeric repeat-binding factor 2 (TRF2) protein-modulating compounds and have a preventive action on deoxyribonucleic acid (DNA) double-strand breaks. In addition, cosmetic compositions that include at least one peptide of general formula (I) in a physiologically acceptable medium are disclosed along with methods for preventing and/or treating cutaneous signs of aging and photoaging.Type: GrantFiled: April 27, 2012Date of Patent: August 19, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20140227279Abstract: Compositions and methods for the treatment of autoimmune and inflammatory diseases are disclosed.Type: ApplicationFiled: August 9, 2012Publication date: August 14, 2014Applicant: Lankenau Institute for Medical ResearchInventors: Lisa Laury-Kleintop, Laura Mandik-Nayak, George C. Prendergast, James Duhadaway
-
Patent number: 8802635Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.Type: GrantFiled: August 9, 2013Date of Patent: August 12, 2014Assignees: Oneday—Biotech And Pharma Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
-
Publication number: 20140220070Abstract: The present invention relates to the use of a composition comprising at least one cell membrane fraction or parts thereof, for the reduction of lipolytic activity and/or to retard fat digestion, suppress appetite, body weight and/or lower blood lipids. The invention also relates to the use of said hydrophobic peptide in a pharmaceutical as well as a food composition and methods of treating a mammal with said composition.Type: ApplicationFiled: December 23, 2013Publication date: August 7, 2014Applicant: Thylabisco ABInventors: Per-Ake ALBERTSSON, Charlotte ERLANSSON-ALBERTSSON
-
Publication number: 20140221296Abstract: The invention is directed to methods for extracting phosvitin from egg yolk involving contacting the egg yolk or egg yolk protein granules with a solution having a salt concentration of about 10% to form a mixture; optionally, heating the mixture; adjusting the pH of the mixture to separate phosvitin from other proteins; recovering the phosvitin. The phosvitin extract may be dephosphorylated and hydrolyzed to produce phosvitin phosphopeptides.Type: ApplicationFiled: June 11, 2012Publication date: August 7, 2014Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTAInventors: Jianping Wu, Bo Lei, Jiandong Ren
-
Publication number: 20140219981Abstract: The present invention relates in general to the field of tissue engineering and more specifically to amphiphilic peptides and peptide matrices thereof useful in vitro and in situ biomineralization and inducing bone repair. The present invention provides peptides, which are useful in hydrogels and other pharmaceutical compositions, and methods and kits of use for bone repair and promotion of biomineralization. Certain hydrogels according to the invention comprise cells within or adhered to the peptide matrix.Type: ApplicationFiled: January 14, 2014Publication date: August 7, 2014Applicant: Ben-Gurion University of the Negev Research and Development AuthorityInventor: Hanna RAPAPORT
-
Patent number: 8796212Abstract: A composition comprising a synthetic growth factor analog comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analog is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.Type: GrantFiled: July 19, 2011Date of Patent: August 5, 2014Assignee: BioSurface Engineering Technologies, Inc.Inventors: Paul O. Zamora, Brent Lee Atkinson, Xinhua Lin, Louis A. Pena
-
Patent number: 8796227Abstract: Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.Type: GrantFiled: January 28, 2013Date of Patent: August 5, 2014Assignee: Biokine Therapeutics Ltd.Inventors: Amnon Peled, Orly Eizenberg, Dalit Vaizel-Ohayon
-
Patent number: 8796226Abstract: Long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer are provided. In particular, the long acting pharmaceutical composition comprises a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection.Type: GrantFiled: August 19, 2010Date of Patent: August 5, 2014Assignee: Mapi Pharma Ltd.Inventors: Ehud Marom, Shai Rubnov
-
Publication number: 20140213534Abstract: Compositions for and methods of preventing or reducing the severity intestinal hyperpermeabilization in an individual are disclosed. Compositions for and methods of preventing or reducing the severity of a disease or condition caused or exacerbated by intestinal hyperpermeabilization in an individual identified as being at risk of a disease or condition caused or exacerbated by intestinal hyperpermeabilization are also disclosed. Compositions for and methods of treating an individual who has been identified as having a disease or condition caused or exacerbated by intestinal hyperpermeabilization are additionally disclosed.Type: ApplicationFiled: April 27, 2012Publication date: July 31, 2014Applicant: Thomas Jefferson UniversityInventors: Scott A. Waldman, Adam E. Snook, Peng Li, Jieru Egeria Lin
-
Patent number: 8790653Abstract: The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides.Type: GrantFiled: November 1, 2011Date of Patent: July 29, 2014Assignee: Yeda Research and Development Co. Ltd.Inventors: Johannes Herkel, Irun R. Cohen, Varda Rotter, Ansgar W. Lohse, Neta Erez, Avishai Mimran, Na'aman Kam
-
Publication number: 20140206629Abstract: The invention relates to inhibition of SDF-1? expression in subacromial bursa cells by CXCR-4 inhibitors. Bursal cell migration in response to SDF-? stimulation is also decreased in the presence of CXCR4 inhibitors. Accordingly, provided are methods for treating or ameliorating a musculoskeletal disorder.Type: ApplicationFiled: February 17, 2012Publication date: July 24, 2014Applicant: RHODE ISLAND HOSPITALInventor: Theodore A. Blaine
-
Patent number: 8785400Abstract: The present invention provides methods and kits for treating diseases and conditions associated with impaired pancreatic function. The present invention further provides methods of stimulating islet cell neogenesis and stimulating islet cell differentiation from progenitor cells.Type: GrantFiled: November 21, 2007Date of Patent: July 22, 2014Assignee: CureDM Group Holdings, LLCInventors: Claresa S. Levetan, Loraine V. Upham
-
Publication number: 20140199318Abstract: The invention relates to means for detecting, binding, removing and/or neutralising agonistic antibodies associated with dementia, preferably Alzheimer's disease or vascular dementia.Type: ApplicationFiled: July 13, 2012Publication date: July 17, 2014Applicants: MAX-DEL-BRUCK-CENTRUM FUR MOLEKULARE MEDIZIN, E.R.D.E.-AAK-DIAGNOSTIK GMBHInventors: Marion Bimmler, Peter Karczewski, Petra Hempel
-
Publication number: 20140200174Abstract: Disclosed are a peptide for promoting osteogenesis and vascularization, and the use thereof. The peptide has a low molecular weight so that it can be economically produced. In addition, it promotes osteoblastic differentiation, thus inducing osteogenesis. Further, the peptide can promote the expression of VEGF, resulting in vascularization. Accordingly, the peptide is useful for the delay of the onset of ischemic diseases and the therapy of ischemic diseases.Type: ApplicationFiled: January 13, 2014Publication date: July 17, 2014Applicant: Chonnam National University HospitalInventors: Taek Rim YOON, Hyung Keun KIM, Ji Hyun KIM, Myung Ho JEONG
-
Patent number: 8778891Abstract: Peptides activating dermatopontin in the skin and cosmetic compositions including such peptide, in a physiologically suitable medium, are described. Methods of treating the cutaneous signs of aging and photoaging, and in particular wrinkles, sagging, and loss of volume and elasticity of the skin are also described.Type: GrantFiled: November 7, 2011Date of Patent: July 15, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8779091Abstract: A selective targeting method is disclosed comprising contacting a library of ligands, particularly a peptide library, with an anti-target to allow the ligands to bind to the anti-target; separating the non-binding ligands from the anti-target bound ligands, contacting the non-binding anti-target ligands with a target allowing the unbound ligands to bind with the target to form a target-bound ligand complex; separating the target-bound ligand complex from ligands which do not bind to the target, and identifying the target-bound ligands on the target-bound ligand complex wherein the target-bound ligands have a KD in the range of about 10?7 to 10?10 M. Additionally claimed are the ligands identified according to the method.Type: GrantFiled: October 23, 2012Date of Patent: July 15, 2014Assignee: Danisco US Inc.Inventors: Christopher J. Murray, Pilar Tijerina, David A. Estell, Yiyou Chen
-
Patent number: 8779090Abstract: Peptides that act as GC-C receptor agonists and contain at least one D-cys and are useful for the treatment of diuresis and heart disease as well as other disorders are described.Type: GrantFiled: February 26, 2008Date of Patent: July 15, 2014Assignee: Ironwood Pharmaceuticals, Inc.Inventors: Daniel Zimmer, Angelika Fretzen, Mark Currie, G. Todd Milne
-
Publication number: 20140194358Abstract: Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration.Type: ApplicationFiled: October 28, 2013Publication date: July 10, 2014Applicant: Children's Medical Center CorporationInventors: Avner Adini, Robert D'Amato
-
Patent number: 8772229Abstract: The invention provides inhibitors of ghrelin O-acyltransferase, and methods of making and using them. In some embodiments, the invention provides bisubstrate analog inhibitors of ghrelin O-acyltransferase, which can be effective in treating, for example, obesity and diabetes mellitus.Type: GrantFiled: September 18, 2009Date of Patent: July 8, 2014Assignee: The Johns Hopkins UniversityInventors: Philip A. Cole, Bradley P. Barnett, Yousang Hwang, Jef D. Boeke
-
Patent number: 8772225Abstract: The present invention relates to the diagnosis of neurological disorders, more specifically to the diagnosis of multiple sclerosis. A biomarker panel is provided which can be used to detect if a subject has multiple sclerosis. Also described are methods of identification of such biomarkers.Type: GrantFiled: April 14, 2008Date of Patent: July 8, 2014Assignee: Universiteit HasseltInventors: Veerle Somers, Pieter Stinissen
-
Publication number: 20140186379Abstract: The present invention discloses novel macromolecule transduction domain (MTD) peptides which facilitate the traverse of a biologically active molecule across the cell membrane. Also disclosed are polynucleotides encoding the MTD peptides, methods of identifying the MTD peptides; methods of genetically engineering a biologically active molecule to have cell permeability by using the MTD peptides, methods of importing a biologically active molecule into a cell by using the MTD peptides, and uses thereof.Type: ApplicationFiled: November 27, 2013Publication date: July 3, 2014Applicant: PROCELL THERAPEUTICS INC.Inventors: Dae Woong JO, Jae Sun Ko, Jin Sook Kim, Kyung Mi Park, Jin Kyung Song, Jung Hee Lim, Thi Thuy Nga Do, Thi Lan Phuong Do, Minh Tam Duong
-
Publication number: 20140187494Abstract: The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, inhibit the interaction of MUC1 with NF-?B or a STAT, and block inflammatory response mediated by NF-?B or STAT signaling.Type: ApplicationFiled: December 23, 2013Publication date: July 3, 2014Applicants: GENUS ONCOLOGY, LLC, DANA-FARBER CANCER INSTITUTE, INC.Inventors: Donald W. KUFE, Surender KHARBANDA
-
Patent number: 8765683Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful in cancer therapy.Type: GrantFiled: January 29, 2012Date of Patent: July 1, 2014Assignee: Biokine Therapeutics Ltd.Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham
-
Patent number: 8765689Abstract: Peptide compounds of the general formula (I) R1-(AA)n-X1—X2-Arg-Glu-Met-Asn-Trp-X3-(AA)p-R2 modulating the survivin protein are described. Furthermore, cosmetic or pharmaceutical compositions, including at least one peptide of the general formula (I), in a physiologically acceptable medium are described. Additionally, methods for treating the cutaneous signs of ageing and photo-ageing, treating the skin against external aggressions, and limiting hair loss and/or stimulating hair growth are described.Type: GrantFiled: January 13, 2011Date of Patent: July 1, 2014Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto